|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.26 / 1.51|
Positive Results in a Number of Clinically Relevant Parameters Suggest Improved Lung Function with alidornase alfa
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
Shipment Size for Fourth Quarter of 2017 Represents Annual Revenues of approximately $42 Million
Approval further supports the advanced ongoing discussions with the Brazilian Ministry of Health for the supply of a significant amount of alfataliglicerase for Gaucher patients in Brazil
Six Sites Activated Across the United States and Europe with additional patients currently in the screening process for potential inclusion in trial